AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.88
−4.29%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 98.58x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.51x
- Price / sales
- 120.97x
- Price / cash flow
- -16.16x
Enterprise value
- Enterprise value
- $710.9M
- EV / sales
- 70.66x
- EV / EBITDA
- -9.14x
- EV / EBIT
- -8.15x
- Market cap
- $1.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026